Gpc3 - glypican 3 Gene

Also Known as OCI-5

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 25236

Summary

Predicted to enable peptidyl-dipeptidase inhibitor activity. Acts upstream of or within negative regulation of canonical Wnt signaling pathway and positive regulation of Wnt signaling pathway, planar cell polarity pathway. Is anchored component of plasma membrane. Used to study hepatocellular carcinoma. Human ortholog(s) of this gene implicated in Simpson-Golabi-Behmel syndrome type 1 and nephroblastoma. Orthologous to human GPC3 (glypican 3). [provided by Alliance of Genome Resources, Apr 2022]

Gpc3 Products (1)

mRNA Protein Name
NM_012774.2 NP_036906.2 glypican-3 precursor

Gene Ontology

  • Biological Process
  • Cellular Component
Biological Process GO Annotation Evidence References Source
acts upstream of or within negative regulation of canonical Wnt signaling pathway IDA
IDA: Inferred from direct assay
15537637 RGD
acts upstream of or within positive regulation of Wnt signaling pathway, planar cell polarity pathway IDA
IDA: Inferred from direct assay
15537637 RGD
acts upstream of or within positive regulation of Wnt signaling pathway, planar cell polarity pathway IGI
IGI: Inferred from genetic interaction
15537637 RGD
Cellular Component GO Annotation Evidence References Source
located in plasma membrane IDA
IDA: Inferred from direct assay
7487896 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

glypican-3

  • defective in Simpson-Golabi-Behmel overgrowth syndrome

  • intestinal protein OCI-5

  • proteoglycan GPC3

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-153360 MC-GGFG-AM-(10Me-11F-Camptothecin) Inhibitor 98.99% Phase 1
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P99013 Codrituzumab Inhibitor 99.07% Phase 2

Pre-clinical Phase

Bioactive Molecules (12)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P10888A GPC3 targeting peptide 1 TFA 99.40% Unkown
HY-W1124925 DOTA-GPC3 targeting peptide 2 Ligand 98.83% Unkown
HY-182099 DSPE-PEG1000-DHLASLWWGTEL / Unkown
HY-182099A DSPE-PEG2000-DHLASLWWGTEL / Unkown
HY-182099B DSPE-PEG3400-DHLASLWWGTEL / Unkown
HY-182099C DSPE-PEG5000-DHLASLWWGTEL / Unkown
HY-185742 ZW-251 Inhibitor / Unkown
HY-P11618 10P3Me Ligand / Unkown
HY-RS05628 GPC3 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-P10888 GPC3 targeting peptide 1 / Unkown
HY-RS16630 Gpc3 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23065 Gpc3 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
Inhibitory Antibodies (6)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990840 Anti-GPC3 Antibody (YP7) Inhibitor ≥95.0% Unkown
HY-P990841 Anti-pan-Glypican Antibody (HS20) Inhibitor 99.44% Unkown
HY-P992011 CAT-07 Inhibitor / Unkown
HY-P992457 SAR444200 Activator / Unkown
HY-P992514 ZW-251 Antibody Inhibitor / Unkown
HY-P991448 MDX-1414 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gpc3 NCBI NCBI:2719